Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Fleischmann

Showing results (131-140 of 160) with videos related to

Pageof 16
Sort By:
Transfusion|February 1, 1991
Selective in vivo removal of rheumatoid factor by an extracorporeal treatment device in rheumatoid arthritis patientsH M Lazarus, S B Cohen, D O Clegg, et al.
The American Journal of Medicine|October 30, 1987
Controlled evaluation of nabumetone in the treatment of active adult rheumatoid arthritis. Nabumetone versus naproxen double-blind parallel studyF B Vasey, B F Germain, L R Espinoza, et al.
The American Journal of Medicine|October 30, 1987
Six-month multi-center study comparing nabumetone with naproxen in the treatment of osteoarthritisE J Pisko, B I Bockow, P Box, et al.
The Journal of Rheumatology|March 3, 2011
Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trialEdward C Keystone, Jeffrey R Curtis, Roy M Fleischmann, et al.
NPJ Precision Oncology|April 23, 2024
Inflammatory pathways confer resistance to chemoradiotherapy in anal squamous cell carcinomaD Martin, F Rödel, S Hehlgans, et al.
Arthritis Care & Research|October 20, 2010
Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritisMichael E Weinblatt, Joan M Bathon, Joel M Kremer, et al.
The Journal of Rheumatology|July 17, 2016
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 TrialMaurizio Cutolo, Gary E Myerson, Roy M Fleischmann, et al.
Annals of the Rheumatic Diseases|November 5, 2020
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritisRoy M Fleischmann, Ricardo Blanco, Stephen Hall, et al.
Arthritis Care & Research|July 18, 2013
Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled studyPaul Emery, Roy M Fleischmann, Mittie K Doyle, et al.
Annals of the Rheumatic Diseases|October 31, 2007
Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitisJ C Davis, D M van der Heijde, J Braun, et al.
Pageof 16

Showing results (131-140 of 160) with videos related to

Sort By:
Pageof 16
Transfusion|February 1, 1991
Selective in vivo removal of rheumatoid factor by an extracorporeal treatment device in rheumatoid arthritis patientsH M Lazarus, S B Cohen, D O Clegg, et al.
The American Journal of Medicine|October 30, 1987
Controlled evaluation of nabumetone in the treatment of active adult rheumatoid arthritis. Nabumetone versus naproxen double-blind parallel studyF B Vasey, B F Germain, L R Espinoza, et al.
The American Journal of Medicine|October 30, 1987
Six-month multi-center study comparing nabumetone with naproxen in the treatment of osteoarthritisE J Pisko, B I Bockow, P Box, et al.
The Journal of Rheumatology|March 3, 2011
Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trialEdward C Keystone, Jeffrey R Curtis, Roy M Fleischmann, et al.
NPJ Precision Oncology|April 23, 2024
Inflammatory pathways confer resistance to chemoradiotherapy in anal squamous cell carcinomaD Martin, F Rödel, S Hehlgans, et al.
Arthritis Care & Research|October 20, 2010
Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritisMichael E Weinblatt, Joan M Bathon, Joel M Kremer, et al.
The Journal of Rheumatology|July 17, 2016
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 TrialMaurizio Cutolo, Gary E Myerson, Roy M Fleischmann, et al.
Annals of the Rheumatic Diseases|November 5, 2020
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritisRoy M Fleischmann, Ricardo Blanco, Stephen Hall, et al.
Arthritis Care & Research|July 18, 2013
Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled studyPaul Emery, Roy M Fleischmann, Mittie K Doyle, et al.
Annals of the Rheumatic Diseases|October 31, 2007
Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitisJ C Davis, D M van der Heijde, J Braun, et al.
Pageof 16